Everyday Health shares their favorite psoriasis organizations to help you educate yourself, spread awareness, and connect ...

A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...

Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...

Zasocitinib demonstrated superiority over deucravacitinib for the treatment of moderate to severe plaque psoriasis, according ...

An integrated multi-omics study identifies four shared genes and folic acid as a potential therapeutic link between psoriasis ...

There’s an interesting relationship between psoriasis and exercise: While the condition can make playing sports and working ...

Zasocitinib was 2.5 times more effective than deucravacitinib at helping patients with plaque psoriasis achieve completely clear skin, based on the first head-to-head test.

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

Add Yahoo as a preferred source to see more of our stories on Google. More than eight million people in the United States have the autoimmune skin condition known as psoriasis, according to the ...

Psoriasis is an inflammatory condition that causes thick, scaly patches on the skin that are flaky and shed easily. Symptoms can worsen with skin injury - through scratching, rubbing, or chafing - in ...

Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of ...

I’ve had psoriasis since I was 5 years old. It started as a little patch on my left ankle—I remember thinking, What’s this ...